To determine the impact of high-resolution (HR) HLA typing with outcomes after UCBT, DNAs of 122 pairs were analysed for HLA class I and class II mismatches (MM) based on HR typing. For HLA-A, -B on low-resolution typing and -DRB1 on HR typing, the following MM situation resulted: no MM (13%), one MM (40%), two MM (36%), three MM (8%), four MM (3%). For A, B, C, DR and DQ based on HR typing the following MM occurred: No MM (4%), one MM (10%), two MM (15%), three MM (22%), four MM (25%), five MM (12%), six MM (6%), seven MM (3%), eight MM (2%). There was no significant association between number of MM (HR) for both HLA-A, -B and -DRB1 and HLA-A, -B, -C, -DRB1 and DQB1 and aGvHD grade II-IV. There was a trend that MM in class I HR were associated with neutrophil recovery; HLA-A locus typing analysed in HvG direction was associated with reduced cumulative incidence of engraftment (P ¼ 0.04), the same for C-KIR in HvG direction (P ¼ 0.01). No significant correlation was found between numbers of HLA-MM on the HR level with 2-year survival. The analysis shows that the degree of mismatching in UCBT is even higher than expected.
cord blood transplantation Hematopoietic stem cell transplantation from an unrelated cord blood (CB) donor is now standard practice for the treatment of malignant and nonmalignant haematological disorders; over 3288 documented unrelated cord blood transplants (UCBT) have been performed from the joined NETCORD inventory as of September 2004. In contrast to unrelated bone marrow transplantation where HLA disparities between the patient and the donor result in increased severe GvHD and graft rejection, [1] [2] [3] the majority of CB grafts were HLA disparate at one to three antigens, resulting in a remarkably low incidence and severity of GvHD. [4] [5] [6] [7] Although the incidence of aGvHD was lower in patients with six of six HLA antigens as opposed to the mismatched patient group, the incidence of aGvHD II-IV did not associate with the number of HLA disparities in the majority of studies. [4] [5] [6] 8 In fact, the lack of correlation between GvHD occurrence and donor/recipient diversity in patients given a UCBT could be explained by the fact that some mismatches for HLA-class I antigens may have been undetected by conventional HLA-serology/low-resolution typing for HLA-A and -B. At present the majority of transplant centres/cord blood banks select CB units for a respective patient based on HLA-A, -B low-resolution typing and -DRB1 HR typing. In contrast to bone marrow transplantation, where in the meantime HLA class I (A, B, C) and HLA class II (DRB1 and DQB1) high-resolution typing have been implemented for donor selection to minimize the risk of the two obstacles for successful unrelated stem cell transplantation, GvHD and graft rejection, 2, 3, 9 no HLA class I and II subtyping data are available for UCBT. Moreover, in contrast to publications concerning unrelated bone marrow donors where mismatches were analysed not only on an overall basis, but also for GvHD or host-versus-graft (HvG), the data are lacking for UCBT. In the present retrospective study, we assess for the first time patient/donor combinations using high-resolution DNA typing for both HLA class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) loci. The analysis shows the large HLA disparities between recipient and donor up to 8/10 mismatches on the HR typing level and evaluates the correlation of HLA disparities with engraftment, acute GvHD, transplant-related mortality and survival.
Patients and methods

Patients
A total of 122 patients (91 children, 31 adults) underwent transplantation with unrelated CB from the CB bank in Du¨sseldorf between October 1996 and 2003 in 21 countries at 60 transplant centres (20 non-EBMT and 40 EBMT centres). The median age of the patients was 6.9 years (0.3-48.4 years). The median follow-up was 30.1 months (2.7-84.8). Further clinical details of the patients and their respective donors are reported in Table 1 . Patient/CB donor pairs were included in the analysis on the basis of available DNA samples obtained at the time of HLA typing, single and nonexpanded graft and a minimum of 3-month follow-up data. Information on these patients was collected through the Eurocord Registry in Paris and the Cord Blood Bank in Du¨sseldorf. Ambiguities in the follow-up forms were directly resolved by contact with the transplant centres or Eurocord.
Conditioning regimen and cytomegalovirus serology
The conditioning regimen varied according to type of disease, disease status, previous treatment at the time of transplantation and the individual transplant centre policy for unrelated mismatched transplants. The details of the preparative regimens and the use of anti-T lymphocyte monoclonal or polyclonal antibodies are reported in Table 1 . CMV serology status of the patients was documented before transplantation.
HLA typing and GvHD prophylaxis
All CB samples as well as the patients' blood samples were typed before transplantation in Du¨sseldorf by low-resolution DNA typing for HLA-A and -B and by highresolution DNA typing for HLA-DRB1 alleles as described previously. For this retrospective analysis, HLA class I (-A, -B, -C) and class II alleles (-DRB1 and -DQB1) were determined by sequencing. Mismatches were either counted in GvH and HvG direction, or in HvG or GvH direction alone.
The transplant centres used their own protocols for GvHD prophylaxis. The most commonly used GvHD prophylaxis was the combination of cyclosporine A (CsA) and steroids, CsA alone, or the combination with methotrexate (MTX). Further details on GvHD prophylaxis are reported in Table 1 . Once clinical aGvHD was diagnosed, standard therapy was administered with steroids, according to each centre's policy.
Endpoints with statistical analysis
Hematopoietic recovery. Neutrophil recovery was analysed, and was defined by a neutrophil count of 40.5 Â 10 9 /l for three consecutive days and platelet recovery (defined as untransfused platelet count 420 Â 10 9 /l). Failure of engraftment was defined by the absence of blood count recovery at day 60 or by cases of required second transplantation or hematopoietic reconstitution with autologous cells.
Graft-versus-host disease. Acute GvHD II-IV was diagnosed and graded at each transplant centre according to the Seattle criteria. 10 All patients were considered at risk for the occurrence of GvHD from day 1 after transplant. 5 GradesXII were counted as aGvHD. Chronic GvHD was defined according to standard criteria. Patients surviving for more than 100 days after transplant with sustained donor engraftment were considered eligible for assessment of cGvHD.
Early transplant-related mortality (TRM) was defined as all causes of nonleukemic death occurring within 100 days after transplant.
Overall survival was defined as time between transplant to death due to any cause. The median follow-up time was 30.1 months (range 2.7-84.8). The minimal follow-up time was 3 months for the patients that were alive and the day of death for the patients who died before day 100. 
Statistical analysis
Patient and donor-(age, weight, sex and sex matching, CMV serology, ABO compatibility, number of HLA disparities according to low-or high-resolution typing and in GvH or HvG direction), disease-(malignant vs nonmalignant, prognostic score for malignant diseases, previous autologous or allogeneic transplant), and transplant-related (NC and CD34 cells collected and infused per kg, conditioning regimen, GvHD prevention) variables were analysed for their potential prognostic value on each of the aforementioned endpoints. Univariate analysis was used to identify risk factors of survival by means of log-rank tests. For assessment of prognostic factors of neutrophil recovery, acute GvHD (grade II-IV) and TRM, a similar methodology was used in a competing risks setting, death being treated as a competing event.
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Univariate analyses were then performed using Gray's test. A multivariate analysis was not performed due to the relatively small number of patients. All analyses were performed using the cmprsk package (developed by Gray, June 2001) on Splus 2000 software and SPSS software.
Results
Degree of HLA mismatch in the patient/CB donor population
At present CB donors are chosen for the patients employing low-resolution typing techniques for HLA-A and -B loci and high-resolution typing for HLA-DRB1 alleles. Using this approach the patient/CB donor population here was characterized as follows: 16 (13.11%) were HLA matched, 49 (40.16%) had one HLA mismatch, 44 (36.07%) had two HLA mismatches, 10 (8.2%) had three HLA disparities and three patients (2.56%) had four differences. As summarized in Table 2 , the subtyping for the HLA-A-and B-locus in addition to the DRB1 allele increased the number of disparities up to five out of six possible mismatches.
By including all HLA class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) loci in the analysis, the following mismatch situation occurred: Only five (4.1%) of the patients were considered fully compatible (10 out of 10 HLA alleles matched), 12 (9.84%) had only one MM, 19 (15.57%) had two, the majority of the patients had three MM (n ¼ 27, 22.13%) and four MM (n ¼ 31, 25.41%), 15 (12.3%) patients were mismatched at five alleles, seven patients (5.74%) at six alleles, four patients (3.28%) at seven and two patients (1.64%) at eight out of 10 possible alleles.
Association of HLA typing level with neutrophil recovery
The cumulative incidence (CI) of neutrophil recovery at day 60 was 7874% for the total patient group (Figure 1a ) with a median of 24 days (10-57 days). The median time for platelet recovery was 53 days (9-166 days) with 58% CI of platelet engraftment at day 180. In all, 10 patients had no engraftment at day 60. No statistical association between HLA mismatches (6/6 or 10/10) and neutrophil recovery was observed. However, based on HLA HR typing, that is, HLA-A locus typing in the rejection direction (donor's allele not shared by the recipient), one or two A-locus HLA disparities were associated with reduced CI of engraftment (P ¼ 0.04, Table 3 ). The same was observed for the C-KIR epitopes in the rejection (HvG) direction (P ¼ 0.01, Table 3 ). No other statistically significant difference between the number of HLA mismatches, analysed both for total mismatches on the subtyping level for 10/10 antigens and 6/6 antigens, or in GvHD and HvG direction, and engraftment was observed (Table 3) .
Incidence and severity of GvHD and degree of HLA mismatches based on high-resolution HLA typing Out of 122, 57 patients did not develop aGvHD (grade 0 ¼ 47%), 31 developed grade I (25%), 12 developed grade II (10%), 10 developed grade II (8%), and 12 developed grade IV (10%). The CI of acute GVHD (II-IV) at day 100 was 2874% ( Figure 1b) . As shown in Table 3 , there was no statistically significant difference between the number of HLA mismatches analysed both for total mismatches and GvHD direction (donor's allele not shared by the recipient, Table 3 ) on the subtyping level for 10/10 antigens and on the level performed at present when selecting CB for transplantation taking six out of six antigens into consideration. By analysing separately the influence of single alleles (-A, -B, -C, -DR, -DQ) on the subtyping level in GvH direction only for the HLA-class I B-Locus (comparing 0 mismatches vs one and two locus mismatches), it was observed that MM in the B-locus were associated with the incidence of aGvHD II-IV (P ¼ 0.04). However, as shown in Table 3 , only 16% of the patients (n ¼ 6) developed aGvHD II-IV in the group of 0 MM for the B-alleles, whereas 33% (n ¼ 28) developed aGvHD II-IV, if one or two B alleles were disparate. Of the 80 patients who had engrafted and were still alive at day 100, only 13 (13%) developed chronic GvHD. The cumulative incidence at 2 years was 11% (Figure 1c) . Due to the small number of Table 2 Details of HLA class I and class II alleles and antigen matching in the 122 CB-donor/patient pairs patients we were not able to study the association of HLA with the incidence of chronic GVHD.
Early transplant-related mortality
In all, 51 of the 122 patients died of transplant-related complications during the first 100 days after transplantation. The CI of TRM at day 100 was 3274% ( Figure 1d ). Diagnosis (malignant vs nonmalignant, P ¼ 0.01), negative CMV serology (P ¼ 0.0001) and male gender (P ¼ 0.01) were prognostic factors associated with TRM (Table 3) . No association of TRM with number of HLA mismatches was detected.
Impact of the HLA typing level on survival
Univariate statistical analysis revealed that the 2-year overall survival in this heterogeneous group of patients was 4175% (Figure 2a ). As shown in Table 3 , in univariate analysis survival was associated with the CMV serology status of the recipient (P ¼ 0.0004), the recipient gender (P ¼ 0.02), the number of nucleated cells collected (o5.0 Â 10 7 /kg BW) and infused (o4.0 Â 10 7 /kg BW). Analysing survival and number of HLA disparities for the low-resolution HLA-A, -B and -DRB1 subtyping level resulted in a 2-year estimated survival rate of 45% for 0 disparities, 47% for one disparity, 39% for two disparities and 13% for three to four HLA disparities (P ¼ 0.38, Table 3 , Figure 2b ). For the HLA-A, -B, -DRB1 highresolution typing group, the results were as follows: 0 disparities resulted in a 43% estimated 2-year survival, one MM in 52% survival, two MM in 37% survival and three to five MM in 27% survival (P ¼ 0.29, Table 3, Figure 2c ). The association of the number of HLA disparities considering HR level for HLA-A, -B, -C, -DRB1, -DQB1 with 2 years survival was 53% for 0 MM, 32% for one MM, 47% for two MM, 38% for three MM, 41% for four MM and 39% for five to eight MM (grouped due to the small number of patients in each subcategory) (P ¼ 0.97, Table 3 , Figure 2d ).
The causes of death were as follows: relapse/progression (n ¼ 22), GvHD (n ¼ 10), viral infection (n ¼ 11), bacterial infection (n ¼ 6), fungal infection (n ¼ 5), parasitic infection (n ¼ 2), ARDS/IP (n ¼ 5), graft failure (n ¼ 1), VOD (n ¼ 3), MOF (n ¼ 3) and others (n ¼ 5).
Discussion
The results of this study revealed for the first time the large number of actual HLA disparities of 122 recipient/cord blood donor pairs analysed by HLA-A, -B, -C, -DRB1, -DQB1 allelic subtyping. In this limited and heterogeneous group of patients it appears that there is no benefit of Unrelated cord blood transplants.
HLA-class I and II subtyping in unrelated CB transplantation G Kögler et al Table 3 Univariate analysis of Neutrophil recovery, acute GVHD, 100 day TRM and 2 year survival additional high-resolution typing for the HLA-A-, B-, Cand DQ-locus for outcomes after UCBT. In contrast to unrelated bone marrow or adult HSC transplantation, where donor selection on high-resolution DNA typing for both HLA-class I and HLA class II loci has been reported to improve the outcome of unrelated transplantation, [1] [2] [3] 12 the situation in CB transplantation is completely different. The majority of transplant centres search CB only if there is no unrelated matched bone marrow donor available. Although more than 86 000 unrelated CB units are stored worldwide in the joined NETCORD inventory as of September 2004 (www.netcord.org), the majority of transplantations were performed with one to three HLA-disparate transplants typed on a low-resolution level for HLA-A and -B and on a high-resolution level for DRB1. [4] [5] [6] [7] 13 Despite these large HLA disparities, cord blood transplants are associated with a reduced incidence of acute and chronic GvHD, probably because of the immaturity of the donor T cells, the low number of T cells infused, a selective dendritic cell population, 14 and reduced alloreactivity with concomitant reduction in cytokine responses including TNF and IFN-gamma. 15 Moreover, it has also been suggested that the CB cells mature into IL-10-producing cells that aid the induction of tolerance in the transplant setting. 16 As summarized in all publications thus far, the CB nucleated cell dose/kg body weight is regarded as the most critical parameter for engraftment and survival after UCBT. 6, 7 Beyond cell dose, HLA disparities have also been shown to adversely influence survival after cord blood transplantation, 13, 17 influence engraftment, and result in aGvHD III-IV if HLA-class I and II disparities are present. 7 However, in all of these latter studies HLA typing was only performed on a serological/low-resolution level for HLA class I and on a high-resolution level for DRB1. C-locus typing as well as DQB1 typing were not taken into consideration. In addition, HLA disparities were only analysed in total and not separated into the GvH or HvG direction as performed for unrelated bone marrow transplantation. It is interesting to note that Petersdorf et al 1 have already shown in the largest evaluation of unrelated bone marrow transplantation for the Caucasian population that a single HLA class I or class II allele mismatch had no influence on survival and that multiple mismatching for more than one class I allele and simultaneous disparities in class I and II alleles increase the mortality rate. Therefore transplant centres usually select their prospective donors on high-resolution typing for HLA-A, -B, -C, -DR and -DQ and prefer to match, if possible, 10 out of 10 HLA alleles. 2 In unrelated donor BMT no association between single allele (defined exclusively by high resolution) mismatch and outcome could be defined. Conversely, multiple high resolution mismatches or single low-resolution mismatch was associated with increased risk. As documented in Table 2 , the heterogeneity with regard to recipient/CB donor pairs is much higher. Analysing the total number of HLA disparities on a low-resolution level for A, B, HR level DRB1, 16 patients (13.1%) were HLAidentical, but on a HR level taking 10/10 alleles into the analysis, only five patients (4.1%) were really matched on a subtyping level. Here we show that several CB/patient pairs were transplanted with up to eight mismatches, but the majority with three to four mismatches on the highresolution typing level. This heterogeneity on the HR level will make it very difficult to choose the best possible donor for a CB recipient, if the function or the clinical relevance of the single HLA alleles in the context of CB transplantation is not clear. In any case, however, the cell dose of a cord blood unit must be taken into consideration as the most important factor for survival, if a CB donor is chosen. As shown in Table 3 there was no statistically significant difference between the number of HLA disparities, analysed both for total mismatches but also in GvHD direction on the subtyping level for 10/10 antigens, and the development of aGvHD, however, the analysis here is hampered by the low number of patients developing aGvHD. Possibly, due to the small numbers of patients in each group, no statistical evidence for interaction between HLA mismatches (6/6 or 10/10) and engraftment could be observed; however there appears to be a trend that HR A locus typing and C-KIR epitope incompatibility in the HvG direction reduce the neutrophil engraftment rate, which might be in accordance with Petersdorf et al, 18 who showed that HLA-C disparity is associated with graft failure after unrelated BMT. Further efforts should focus on larger retrospective analyses of HLA high-resolution subtyped recipient/CB donor pairs to provide more information on the significance of allele mismatches and their relevance for GvHD, engraftment and TRM as recently shown by Flomenberg et al 3 on 1874 donorrecipient pairs in unrelated bone marrow transplantation. The data presented in this study here show that further high-resolution typing for HLA-A, -B, -C and -DQ does not improve long-term clinical outcome after cord blood transplantation. However, due to the small number of patients in each subcategory no multivariate analysis could be performed. However, it was interesting to see from the analyses on 1874 unrelated bone marrow transplantations that low-resolution mismatches had a more severe impact on survival than mismatches detectable only with highresolution typing techniques, which is similar to cord blood transplants analysed here, but with a much higher HLA disparity. 3 
